ACET - Adicet Bio Inc logo

Adicet Bio Inc

ACET

Adicet Bio develops allogeneic gamma delta T cell therapies targeting autoimmune diseases and cancer. Its lead candidate, prulacabtagene leucel, targets CD20, while ADI-212 aims at prostate-specific membrane antigen, enhancing cancer treatment options.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 5 years ago โ†’$33today

Score Overview

1 Year
Scoreโ€”
Net Growth15.26%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score3.4
Net Growth-59.64%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-100.00%
Rev Trend20%
Revenue Consistencyโ€”
All Time
Score
Net Growth-8x
Net Trend38%
Net Income Consistency
Rev Growth-100.00%
Rev Trend25%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Adicet Bio Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ACET does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 4.28โ€”
1 Year2025-10-22
$ 14.59-70.66%
5 Years2021-10-22
$ 129.60-96.70%
All Time2018-01-26
$ 1.89K-99.77%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 98M$ 33M
2025$ 0.00-$ 116M$ 158M
2024$ 0.00-$ 117M$ 176M
2023$ 0.00-$ 142M$ 159M
2022$ 24M-$ 69M$ 257M
2021$ 9M-$ 61M$ 277M
2020$ 17M-$ 36M$ 94M
2019$ 995K-$ 28M$ 62M
IPO2018$ 8M-$ 9M$ 108M
ACET - Adicet Bio Inc logo

Adicet Bio Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 17M to $ 0.00 and net income went from -$ 36M to -$ 116M. Revenue increased in 1 of those 5 years; net income in 3.

Adicet Bio Inc currently holds a 5-year HDB Score of 3.4 out of 10. How the HDB Score is calculated.

Membership

Explore ACET with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies